Cargando…

450. Evaluation of Linezolid Pharmacokinetics in Obese Patients with Severe Skin and Soft-Tissue Infections

BACKGROUND: Linezolid is an oxazolidinone antibiotic with broad activity against Gram-positive bacteria and serves as an option for treating severe skin and soft-tissue infections (SSTIs). Adult FDA-labeled dosing is fixed at 600 mg IV/PO twice daily. Although conflicting, current literature is sugg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blackman, Alison L, Jarugula, Praneeth, Nicolau, David P, Ho Chui, Sai, Joshi, Manjari, Gopalakrishnan, Mathangi, Heil, Emily
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809085/ http://dx.doi.org/10.1093/ofid/ofz360.523

Ejemplares similares

1370. Role of Clindamycin Versus Linezolid for Serious Group A Streptococcal Infections
por: Heil, Emily, et al.
Publicado: (2021)

Linezolid in the treatment of HIV-infected patients with complicated skin and soft tissue infections
por: Khachatryan, N, et al.
Publicado: (2007)

Effect of coadministration of rifampicin on the pharmacokinetics of linezolid: clinical and animal studies
por: Hashimoto, Satsuki, et al.
Publicado: (2018)

A Review of Population Pharmacokinetic Analyses of Linezolid
por: Bandín-Vilar, Enrique, et al.
Publicado: (2022)

Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI)
por: So, Wonhee, et al.
Publicado: (2014)

Pharmacokinetics of Linezolid and Ertapenem in experimental parapneumonic pleural effusion
por: Saroglou, Maria, et al.
Publicado: (2010)

Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin
por: Estes, Kerry S, et al.
Publicado: (2010)

Effects of a rifampicin pre-treatment on linezolid pharmacokinetics
por: Okazaki, Fumiyasu, et al.
Publicado: (2019)

Efficacy and safety of linezolid compared with other treatments for skin and soft tissue infections: a meta-analysis
por: Li, Yan, et al.
Publicado: (2018)

Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin
por: Eckmann, Christian, et al.
Publicado: (2010)

A Cross-sectional Analysis of Linezolid in Combination with Methadone or Buprenorphine as a Cause of Serotonin Toxicity
por: Traver, Edward C, et al.
Publicado: (2022)

Predicting Maternal and Infant Tetrahydrocannabinol Exposure in Lactating Cannabis Users: A Physiologically Based Pharmacokinetic Modeling Approach
por: Shenkoya, Babajide, et al.
Publicado: (2023)

The impact of initial antibiotic therapy (linezolid, vancomycin, daptomycin) on hospital length of stay for complicated skin and soft tissue infections
por: Szczypinska, Ewa, et al.
Publicado: (2013)

Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis
por: Litjens, Carlijn H. C., et al.
Publicado: (2023)

Pharmacokinetics of linezolid in critically ill patients undergoing continuous venovenous hemofiltration
por: Meyer, B, et al.
Publicado: (2004)

Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis
por: Zhang, Haoyue, et al.
Publicado: (2023)

In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid and tedizolid
por: Vanegas Múnera, Johanna Marcela, et al.
Publicado: (2017)

Clindamycin Plus Vancomycin Versus Linezolid for Treatment of Necrotizing Soft Tissue Infection
por: Dorazio, Joshua, et al.
Publicado: (2023)

2362. Emergency Department Resource Utilization After Implementation of a Dalbavancin Pathway for Skin and Soft-Tissue Infections
por: Heil, Emily, et al.
Publicado: (2018)

Effects of continuous renal replacement therapy on linezolid pharmacokinetic/pharmacodynamics: a systematic review
por: Villa, Gianluca, et al.
Publicado: (2016)

Population pharmacokinetic analysis of linezolid in patients with different types of shock: Effect of platelet count
por: Wang, Dongdong, et al.
Publicado: (2019)

Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis
por: Gatti, Milo, et al.
Publicado: (2020)

2375. Skin and Soft-Tissue Infections in Patients With Obesity or Heart Failure
por: Ihm, Claudia, et al.
Publicado: (2018)

Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation
por: Millard, James, et al.
Publicado: (2018)

Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
por: Diacon, Andreas H., et al.
Publicado: (2020)

Dose Optimization of Combined Linezolid and Fosfomycin against Enterococcus by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model
por: Mao, Jun, et al.
Publicado: (2021)

Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India
por: Resendiz-Galvan, Juan Eduardo, et al.
Publicado: (2023)

Linezolid Pharmacokinetics and Its Association with Adverse Drug Reactions in Patients with Drug-Resistant Pulmonary Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2023)

Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials
por: Jones, Aksana K., et al.
Publicado: (2020)

Linezolid Resistance in Staphylococci
por: Stefani, Stefania, et al.
Publicado: (2010)

Linezolid-Associated Hypoglycemia
por: Johannesmeyer, Herman Joseph, et al.
Publicado: (2017)

Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin
por: Stephens, Jennifer M, et al.
Publicado: (2013)

Comparative Efficacy and Safety of Vancomycin, Linezolid, Tedizolid, and Daptomycin in Treating Patients with Suspected or Proven Complicated Skin and Soft Tissue Infections: An Updated Network Meta-Analysis
por: Feng, Jingjuan, et al.
Publicado: (2021)

Linezolid-resistant enterococci in Polish hospitals: species, clonality and determinants of linezolid resistance
por: Gawryszewska, I., et al.
Publicado: (2017)

The Synergistic Activity of Rhamnolipid Combined with Linezolid against Linezolid-Resistant Enterococcus faecium
por: Chang, Qingru, et al.
Publicado: (2023)

Pharmacokinetic/pharmacodynamic analysis of linezolid in critically ill patients with severe sepsis treated with renal replacement therapy
por: Barrasa González, H, et al.
Publicado: (2015)

Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation
por: Soraluce, Amaia, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Analysis of Tedizolid Phosphate Compared to Linezolid for the Treatment of Infections Caused by Gram-Positive Bacteria
por: Rodríguez-Gascón, Alicia, et al.
Publicado: (2021)

Applying pharmacokinetic/pharmacodynamic measurements for linezolid in critically ill patients: optimizing efficacy and reducing resistance occurrence
por: El-Gaml, Rasha M., et al.
Publicado: (2022)

Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers
por: Pal, Arindam, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e5ohif1kdu5cq7000l31366iv7